Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

I am not a Healthcare Professional
Prescribing Information LYNPARZA (olaparib) United Kingdom
Adverse Event Reporting

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK

AstraZeneca-logo
  • Our Medicines
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
        • WAINZUA®▼(eplontersen)
      • Chronic Kidney Disease (CKD)
        • FORXIGA® (dapagliflozin)
      • Heart Failure
        • FORXIGA® (dapagliflozin)
      • Hyperkalaemia
        • LOKELMA® (sodium zirconium cyclosilicate)
      • Type 2 Diabetes (T2D)
        • FORXIGA® (dapagliflozin)
    • Oncology
      • Breast Cancer
        • LYNPARZA® (olaparib)
        • TRUQAP®▼(capivasertib)
      • Bladder Cancer
        • IMFINZI® (durvalumab)
      • Endometrial Cancer
        • IMFINZI® (durvalumab)
        • LYNPARZA® (olaparib)
      • Gastrointestinal Cancer
        • IMFINZI® (durvalumab)
        • IMJUDO®▼(tremelimumab)
      • Lung Cancer
        • IMFINZI® (durvalumab)
        • TAGRISSO® (osimertinib)
      • Ovarian Cancer
        • LYNPARZA® (olaparib)
      • Prostate Cancer
        • LYNPARZA® (olaparib)
        • ZOLADEX® (goserelin)
    • Respiratory
      • Asthma
        • TEZSPIRE®▼ (tezepelumab)
        • SYMBICORT® (budesonide/formoterol)
      • Chronic Obstructive Pulmonary Disease(COPD)
        • TRIXEO AEROSPHERE® (formoterol fumarate dihydrate/glycopyrronium/budesonide)
        • BEVESPI® (glycopyrronium/formoterol fumarate dihydrate)
    • Vaccines
      • Flu
        • FLUENZ® nasal spray suspension (influenza vaccine, live attenuated, nasal)
  • Therapy Areas
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
      • Chronic Kidney Disease (CKD)
      • Heart Failure
      • Hyperkalaemia
      • Type 2 Diabetes (T2D)
    • Oncology
      • Breast Cancer
      • Bladder Cancer
      • Endometrial Cancer
      • Gastrointestinal Cancer
      • Lung Cancer
      • Ovarian Cancer
      • Prostate Cancer
    • Respiratory
      • Asthma
      • Chronic Obstructive Pulmonary Disease(COPD)
    • Vaccines
      • Flu
  • About us
    • AZ Commitment
  • Contact us
  • AstraZeneca UK
  • Lynparza
  • LYNPARZA® (olaparib) | Ovarian Cancer | AstraZeneca & MSD UK
  • LYNPARZA® (olaparib) | Resources
  • Home
  • PAOLA-1
  • SOLO-1
  • HRD Testing
  • Dosing
  • Resources
LYNPARZA® (olaparib) | Resources
Make HER first-line count in the maintenance setting in newly diagnosed aOC Make HER first-line count in the maintenance setting in newly diagnosed aOC

MAKE HER FIRST LINE COUNT
in the maintenance setting in newly diagnosed aOC1

  • Indication

Explore our educational resources to support you and your patients below:

  1. Resources for you
  2. Resources for your patients
  3. Order form

These videos have been organised and funded by AstraZeneca and contain mentions of AstraZeneca’s products.

Expert on demand

(EOD)

 

Interactive virtual sessions giving HCPs

personalised education on

Lynparza (olaparib) for aOC.

 

 

View online

GB-70591 | December 2025

All materials for healthcare professionals are intended to be viewed online.

Ovarian Cancer through a patient centric lens

 

Watch our experts discuss treatment for advanced ovarian cancer, integrating key patient considerations such as survivorship and menopause.

 

View online

GB-75307 | April 2026

All materials for healthcare professionals are intended to be viewed online.

Best practice in advanced ovarian cancer service optimisation

Watch our experts discuss best practices in service optimisation for aOC, such as the latest advancements in care, including surgery and PARP inhibitor clinics, and their impact on service performance.

View online

GB-75308 | April 2026

All materials for healthcare professionals are intended to be viewed online.

Patient materials should be downloaded and shared with patients separately.

Lynparza (olaparib) in advanced ovarian cancer patient booklet

These patient leaflets are available in 6 different languages, please select your preffered language

GB-70592 | December 2025

Select the language/s you would like to download this booklet in:

 

English
Arabic
Polish
Punjabi
Romanian
Urdu
Order printed copies here

Understanding genetic testing in ovarian cancer patient booklet

A booklet to help your patients with advanced ovarian cancer understand genetic testing

Download Order copies

 GB-70594 | December 2025

Fields marked with * are mandatory


Note: Your personal details will not be used for any promotional purposes without your explicit consent.

More details can be found in our Privacy Policy.

If you wish to order hard copy materials, please submit the form below:

Thank you for your submission!

Your request is being processed; the items selected will be delivered as soon as possible.
Please make sure the delivery point is expecting your support materials.



Should you have any questions, check Contact us.

Lynparza tablets therapeutic indications1

Lynparza tablets are indicated as
monotherapy for:

  • The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Lynparza in combination with bevacizumab
is indicated for:

  • The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

Please consult the SmPC for further information before making any prescribing decisions.

BRCA1/2, BRCA1 or BRCA2 mutation; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique; HRD, homologous recombination deficiency; aOC, advanced ovarian cancer.

 

  1. Lynparza (olaparib) Summary of Product Characteristics. 

GB-73642 | February 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Connessiallasalute.it
Connessiallasalute.it

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Terms of use

Privacy Policy

Cookie Policy

Contact Us

LinkedIn

Twitter

© Merck Sharp & Dohme (UK) Limited 2025. All rights reserved.

©2026 AstraZeneca. GB-73125 | January 2026